Fourth European Healthcare Policy Deciders Forum Encouraging and Rewarding Innovation Medicines Policy
Fourth European Healthcare Policy Deciders Forum Encouraging and Rewarding Innovation Medicines Policy Effectiveness and efficiency in resource allocation February 17th – 18th, London Uptake of innovative products across EU countries: How to address existing discrepancies ? Francis Arickx National Institute for Health and Disability Insurance Brussels, Belgium ...“Effective market access and utilisation vary strongly between and within Member States”… 2008, High Level Pharmaceutical Forum Uptake of innovative products across EU countries: How to address existing discrepancies ? 2009 sales per 100.000 inhabitants vs. number of available innovative medicines 50 3 2,5 40 35 2 30 25 1,5 20 1 15 10 0,5 5 0 Source: 0 RIZIV/INAMI & IMS Health, 2010 (data on file) Understanding and measuring pharmaceutical innovation across the European Union Uptake of innovative products across EU countries: How to address existing discrepancies ? sales per 100.000 inhabitants (in mio EURO) number of available innovative medicines 45 REIMBURSE Uptake of innovative products across EU countries: How to address existing discrepancies ? ASAP Uptake of innovative products across EU countries: How to address existing discrepancies ? Innovation Availability Uptake of innovative products across EU countries: How to address existing discrepancies ? Affordability “Truly innovative medicines have a potential to lead to key improvements in health outcomes at the individual and the population levels. If, in addition, these medicines fill an unmet medical need, we propose to call them valuable.” Belgian EU Presidency 2010 Ministerial Conference on Innovation and Solidarity September 2010 Background report: “A call to make valuable innovative medicines accessible in the European Union. Recommendations for a coordinated action to stimulate, measure and valorise pharmaceutical innovation.” Uptake of innovative products across EU countries: How to address existing discrepancies ? INNOVATION and VALUE Unmet Medical Needs Patient and Societal perspective Expectations Offer Based versus Demand Driven Priorities Uptake of innovative products across EU countries: How to address existing discrepancies ? Source: Gartners Hype Cycle for Emerging Technologies 2010 Uptake of innovative products across EU countries: How to address existing discrepancies ? INNOVATION and VALUE Unmet Medical Needs Patient and Societal perspective Expectations Offer Based versus Demand Driven Priorities Uptake of innovative products across EU countries: How to address existing discrepancies ? AVAILABILITY UMN and Priorities Early Dialogue Investment Incentives Fair Reward: IP and Money for Value Uptake of innovative products across EU countries: How to address existing discrepancies ? Locations of Drug Patent Inventors (Top Ten) 250 number of patents 200 150 100 50 0 2001 2002 US Belgium Source: 2003 2004 Japan Switzerland 2005 Canada France Location of pharmaceutical innovation: 2000–2009 Yali Friedman Nature Reviews Drug Discovery 9, 835-836 (November 2010) Uptake of innovative products across EU countries: How to address existing discrepancies ? 2006 UK Sweden 2007 2008 Denmark Germany 2009 Phase III and submission failures: 2007 - 2010 not disclosed 6% financial commercial 7% vs placebo 32% efficacy 66% as add on 29% safety 21% vs active control 5% Source: Thomson Reuters Life Science Consulting, 2010 Uptake of innovative products across EU countries: How to address existing discrepancies ? AFFORDABILITY Cost and Value for Money Sustainability Innovative Financing Mechanisms Solidarity Uptake of innovative products across EU countries: How to address existing discrepancies ? Total health expenditure per capita and GDP per capita, 2008 5 000 4 500 NOR Health expenditure per capita (EUR PPPs) 4 000 CHE LUX2 DEU AUT NLD 3 500 IRE FRA DNK1 BEL ISL SWE GBR FIN ITA GRC1 ESP EU 3 000 2 500 2 000 PRT2 SVN CZE 1 500 1 000 500 0 5 000 SVK HUN LTU EST LVA1 CYP BGR1 ROUPOL TUR1 15 000 25 000 35 000 45 000 55 000 GDP per Capita (EUR PPPs) Source: OECD Health Data 2010; Eurostat Statistics Database; WHO National Health Accounts. Uptake of innovative products across EU countries: How to address existing discrepancies ? 90 9 80 8 70 7 60 6 50 5 40 4 30 3 20 2 10 1 0 Physicians - Hospital Beds HLY the Reality of Europe 0 country Healthy Life Years (HLY) at birth, men, 2005-2007 Hospital beds per 1 000 population, 2008 Source: Practising physicians per 1 000 population, 2008 OECD Health Data 2010; Eurostat Statistics Database; WHO National Health Accounts. Uptake of innovative products across EU countries: How to address existing discrepancies ? AFFORDABILITY Cost and Value for Money Sustainability Innovative Financing Mechanisms Solidarity Uptake of innovative products across EU countries: How to address existing discrepancies ? 2008,The High Level Pharmaceutical Forum: … Member State authorities and stakeholders of the Pharmaceutical Forum should strengthen their efforts in ensuring timely access to valuable innovations and in ensuring access to medicines for all citizens… …Member States are called upon to set clear and common expectations on what innovation they consider valuable and would reward. This will give companies a clear direction on healthcare priorities and indications on the evidence needed by authorities, while bringing authorities clarity on the mid- to long-term budget needs. Companies are called upon to deliver the innovative medicines that society needs. Cooperation with patient organisations should also be encouraged… …National pricing and reimbursement policies should reflect and recognize these expectations and give a consistent reward to benefits considered valuable. National systems on pricing and reimbursement should therefore be well aligned with systems that assess the value of medicines…. Uptake of innovative products across EU countries: How to address existing discrepancies ? Uptake of innovative products across EU countries: How to address existing discrepancies ? DG Industry and Entrepreneurship Commissioner Tajani Process on Corporate Responsibility in the field of Pharmaceuticals three independent platforms : Transparency and ethics in the sector Access to medicines in Europe, in the context of pricing and reimbursement Access to medicines in developing countries with a focus on Africa Uptake of innovative products across EU countries: How to address existing discrepancies ? DG Industry and Entrepreneurship Commissioner Tajani Process on Corporate Responsibility in the field of Pharmaceuticals Access to medicines in Europe, in the context of pricing and reimbursement A Mechanism of coordinated access to orphan medicinal products Capacity building on contractual agreements for innovative medicines Facilitating the supply in small countries Promoting a good governance for non- prescription drugs Market access for biosimilars Uptake of innovative products across EU countries: How to address existing discrepancies ? conclusion Uptake of innovative products across EU countries: How to address existing discrepancies ? Availability Affordability Priorities Solidarity Uptake of innovative products across EU countries: How to address existing discrepancies ? Availability A A Affordability P Priorities S Solidarity Uptake of innovative products across EU countries: How to address existing discrepancies ? thank you Uptake of innovative products across EU countries: How to address existing discrepancies ? Fourth European Healthcare Policy Deciders Forum Encouraging and Rewarding Innovation Medicines Policy Effectiveness and efficiency in resource allocation February 17th – 18th, London Uptake of innovative products across EU countries: How to address existing discrepancies ? Francis Arickx National Institute for Health and Disability Insurance Brussels, Belgium Uptake of innovative products across EU countries: How to address existing discrepancies ?
© Copyright 2024